BREAKING NEWS

BREAKING NEWS

Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

Now Reading:

Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

Text size Aa Aa

FRANKFURT (Reuters) – Germany’s Merck KGaA <MRCG.DE> is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros (616.21 million pounds) in the European Union. Peak sales in the region would be 500-700 million euros for the drug, also known as cladribine, by 2024 or 2025, the diversified chemicals and pharma company said on Thursday. It will decide by the year-end whether to also seek approval in the United States. In 2011, U.S. drug regulators’ concerns about side effects put an end to Merck’s development and marketing plans for the drug but Merck later revived efforts and won approval in Europe. Biogen <BIIB.O>, Novartis <NOVN.S> and Sanofi <SASY.PA> have pulled ahead with oral MS treatments, gradually replacing standard injection therapies and reaching a share of the overall MS market of more than 40 percent.

(Reporting by Ludwig Burger; Editing by Victoria Bryan)
euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.